Cabergoline is the preferred first-line agent for prolactinoma. When treatment at standard doses does not reach the defined targets — or when intolerance prevents adequate dosing — a structured next-line approach is indicated.

Previous Treatment — Failure Condition

The prior regimen used cabergoline as primary medical therapy, with bromocriptine and quinagolide as less commonly used alternatives. This line was insufficient: it did not achieve normalization of serum prolactin levels or meaningful reduction in adenoma size, or ongoing intolerance prevented reaching those goals.

Next-Line Approach — Partial Overview

The protocol involves an intervention within the dopamine agonist class — either a dose-related adjustment or a switch to a different agent depending on the nature of the inadequate response. The full structured regimen specifies the precise clinical path.

Treatment Goals

Normalization of serum prolactin levels and relevant mass shrinkage — defined as a reduction of at least 30% in maximum adenoma diameter.

References

DOI: 10.1038/s41574-023-00886-5

Recurrence or lack of remission should prompt dopamine agonist dose increase or consideration for surgery; intolerability can be addressed by switching to a different dopamine agonist or consideration for surgery.
Escalation to maximally tolerated cabergoline dose is the first step for large residual or growing adenomas that do not respond to lower doses.
If intolerance to oral cabergoline persists, patients can switch to a different dopamine agonist such as quinagolide (a more specific D2R agonist), if available.
The consensus was to define 'resistance' as lack of normalization of prolactin serum levels or lack of relevant mass shrinkage (≥30% reduction in maximum diameter) when treated with standard dopamine agonist doses (7.5–10 mg per day of bromocriptine or 2.0 mg per week of cabergoline) for at least 6 months.

View source ↗

What to Do for Prolactinoma When Cabergoline Does Not Achieve Remission or Is Not Tolerated